Study correction shows Vioxx risks appeared early
<<   June/2006   >>
Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30  

Arts
Movies
Humor
Television
Music

Business
Internet
Finance
Jobs
Investing
Economy

Computers
Software
Hardware
World
Mobile

Games
Video Games
RPGs

Health
Fitness
Medicine
Alternative

Home
Consumers
Cooking

Recreation
Travel
Food
Outdoors

Reference
Psychology
Science
Education

Regional
US
Canada
Europe

Science
NSF
Space
Technology

Society
People
Religion

Sports
Baseball
Soccer
Basketball
 
26/Jun/2006 12:47PM

A correction published Monday to a key study on withdrawn painkiller Vioxx reveals the risk of heart problems was elevated throughout the time people were on the drug and did not develop only after 18 months of use as the drug's maker, Merck & Co., has contended.

The correction in the New England Journal of Medicine supports many doctors' contention that risks showed up with as little as four months of use.

Heart attacks and strokes occurred more frequently after people had been on the drug for at least 18 months, but the actual harm occurred much earlier, said Dr. Jeffrey Drazen, editor-in-chief of the journal, who worked with the authors to correct their original findings of the APPROVe trial, published in March 2005.

"It's a subtle but very critical point," Drazen said.

Cleveland Clinic cardiologist Dr. Steven Nissen, who has challenged the study's conclusions in the past and did so again in a separate letter also published by the medical journal on Monday, agreed.

"A key legal defense in the liability cases has been the suggestion that there was no risk until patients had taken the drug for 18 months," he said. Now, with the correction, "the authors have removed any claim that there was a delay in risk."

The main authors, Dr. Robert Bresalier of the University of Texas' M.D. Anderson Cancer Center and Dr. John A. Baron of Dartmouth Medical School, could not be reached for comment but acknowledge in a letter released by the journal that their statistical analysis had been flawed.

Officials at Merck could not immediately be reached for comment. The company, which paid for the study, acknowledged the flawed analysis last month but claimed it did not change bottom-line results.

Merck faces more than 11,500 lawsuits over Vioxx, a blockbuster arthritis drug until it was pulled from the market in September 2004.

An ongoing trial in Atlantic City, New Jersey, is the seventh case to reach trial. Merck has won half of the previous six.




Recent news in category
Plan B advocates seek access for all
100-year-old: Try cold showers for long life
Morning-after pill to be available without prescription

Global recent news
The joy of reading
Scottish Executive Launches More AntiSectarian Material for Schools
Reflections on Everest 2006

26/Jun/2006 10:33AM
WASHINGTON Reuters) -- People with long-term, low-level exposure to pesticides have a 70 percent higher incidence of Parkinson's disease than people who have not been exposed much to bug sprays, U.S. researchers reported on Monday.

26/Jun/2006 10:26AM
WASHINGTON (Reuters) -- Cell phone emissions excite the part of the brain cortex nearest to the phone, but it is not clear if these effects are harmful, Italian researchers reported on Monday.

26/Jun/2006 9:45AM
KENNETT SQUARE, Pennsylvania (AP) -- Marguerite Harris and her staff of eight provide prenatal care and child immunizations, write prescriptions, and diagnose and treat ailments from diabetes to the sniffles.

25/Jun/2006 8:39PM
WASHINGTON (AP) -- A new test may help scientists answer a perplexing "which came first" question about the development of Alzheimer's disease, possibly pointing the way to earlier diagnosis or even treatment.

23/Jun/2006 5:53PM
GARLAND, Texas (AP) -- When Maria Trevino learned she was pregnant in ninth grade, one of her worries was how she would finish school while raising a child.

Copyright © 2006 Rootio Ltd. All rights reserved.